In Re GeoPharma, Inc. Securities Litigation

399 F. Supp. 2d 432, 2005 WL 2431518

• Court: District Court, S.D. New York
• Decided: September 30, 2005
• Docket: 04 Civ.9463 SAS
• Status: Published

Opinion

OPINION AND ORDER

SCHEINDLIN, District Judge.

I. INTRODUCTION

Plaintiffs bring this putative class action on behalf of certain purchasers of common stock in GeoPharma, Inc. (“GeoPharma”), a publicly-traded pharmaceutical company. The gravamen of plaintiffs’ allegations is that defendants issued a deliberately misleading press release that caused investors to believe that the Food and Drug Administration (“FDA”) had granted GeoPharma approval for a new drug, when in fact the FDA had merely approved a (much less potentially lucrative) medical device. Plaintiffs allege violations of sections 10(b) and 20(a) of the Securities Exchange Act of 1934, and Rule 10b-5 promulgated thereunder by the Securities and Exchange Commission (“SEC”). 1 Defendants now move to dismiss the Complaint pursuant to Federal Rule of Civil Procedure 12(b)(6). 2 For the following reasons, defendants’ motion is granted.

II. THE COMPLAINT

A. The Parties

Plaintiffs are a group of investors who purchased GeoPharriia common stock during the putative class period. 3 Plaintiffs are suing on behalf of a putative class defined as “all persons or entities who purchased the common stock of GeoPharma on December 1, 2004 and/or December 2, 2004, inclusive (the ‘Class Period’), and who were damaged thereby.” 4

GeoPharma manufactures, packages and distributes dietary supplements, over-the-counter drugs, pharmaceuticals and health/beauty care products for companies. 5 Belcher Pharmaceuticals, a unit of GeoPharma, develops and manufactures generic and over-the-counter drugs. 6

Plaintiffs also name three individual defendants, all of whom are officers and directors of GeoPharma. Kotha S. Sekharam is President, 7 Mihir K. Taneja is the Chief Executive Officer and Secretary, 8 and Jugal Taneja is the Chairman of the Board of Directors. 9 All three individual defendants held their current positions during the putative class period. 10

B. The Alleged Scheme

1. Development of Mucotrol

Beginning in early 2004, GeoPharma made several announcements regarding its development of a new product, eventually designated as Mucotrol, intended to treat a condition called mucositis. 11 Mucositis is an inflammation of the mucosa in the mouth, caused by chemotherapy and radiation. 12 According to a GeoPharma press release excerpted in the Complaint, “mucositis affects approximately 15-40% of patients receiving standard-dose chemotherapy and 76-100% of patients receiving higher doses of chemotherapy in bone marrow transplant ... [mjucositis complications may lead to (a) delay in the chemotherapy schedule (b) reduction from the desired dose (c) complications such as pain, dehydration, malnutrition and infection.” 13

On June 29, 2004, GeoPharma filed its annual report with the SEC. According to a GeoPharma Form 10-K filed at that time:

[Fjormulation work and stability studies are currently underway on three other drug products one of which is a product that treats mucositis ... [w]e have developed a formulation using all natural ingredients. Preliminary results indicated promising results in the regeneration of mucosal lining. We have filed a patent on this formulation. Preliminary double blind placebo controlled clinical studies are underway in a prestigious hospital abroad. 14

Defendants again referred to a mucositis drug in a July 13, 2004 press release (entitled “GeoPharma Reports Success in Clinical Studies on Oral Mucositis Drug for Cancer Patients.”) 15 The release reported that GeoPharma had completed a double blind clinical study to evaluate the efficacy of “a patent-pending drug for mucositis in cancer patients.” 16 This press release also stated that “the market potential is estimated to be at $300 million to $500 million.” 17 In the same release, defendant Sekharam was referred to as the drug’s inventor, and was quoted as asserting that this drug was expected to have no side effects. 18

However, while GeoPharma had characterized this new mucositis treatment as a drug, by September 2004 it apparently realized that it was actually a medical device. On September 1, 2004, GeoPharma filed an application with the FDA seeking 510(k) approval 19 to market a medical device by the name of Mucotrol Concentrated Oral gel wafer (“Mucotrol”). 20 Nowhere on the application was Mucotrol referred to as a drug. 21

The FDA granted marketing approval for Mucotrol in a letter dated November 24, 2004. 22 This letter stated that, as required by the 510(k) approval process, the FDA determined that the device is substantially equivalent to other products already in the market. 23 Defendants did not disclose the receipt of this letter until December 2, 2004. 24

Plaintiffs assert that GeoPharma’s sudden shift from development of a drug to a medical device carries great significance. A device has a more limited market than a drug, because a device can only be used for relief once mucositis develops, while a drug can be administered to cancer patients to reduce their chances of developing mucositis in the first place. 25 Similarly, a drug, but not a medical device, shortens hospital stays, a factor important to insurance companies. 26 Finally, while there was no available drug for treatment of mucositis, there were already several medical devices in the market. 27 For these reasons, plaintiffs estimate the potential market for a medical device treating mucositis at $1.2 million, as opposed to $150 million for a drug treatment. 28

2. The December 1 Press Release

On December 1, 2004, prior to the opening of the trading day, GeoPharma issued a press release entitled “GeoPharma, Inc. Receives FDA Approval for Mucotrol™; Manages Mucositis Caused by Radiation and Chemotherapy Required in Cancer Treatment” (“The December 1 Release”). 29 The Release states in pertinent part that “GeoPharma, Inc. today announced that Belcher Pharmaceuticals, Inc., a wholly-owned subsidiary of GeoPharma, Inc., has received approval from the [FDA] for Mucotrol™, a prescription product for the management of oral mucositis/stomatitis.” 30 The release also estimated that, given the number of people who suffer from mucositis, “oncology market potential for Mucotrol™ sales are between $75 million and $800 million per annum and the estimated global market is between $250 million and $1 billion per annum.” 31

Plaintiffs allege two misstatements and an actionable omission in the December 1 Release. 32 First, plaintiffs allege that the Release’s statement that GeoPharma “received approval from the [FDA] for Mucotrol, a prescription product for the management of oral mucositis/stomatitis” is misleading because it faded to make clear that, despite GeoPharma’s earlier statements, Mucotrol was approved as a medical device and not a drug. 33 Second, plaintiffs allege that GeoPharma had a duty to disclose that Mucotrol had existing competition in the field of medical devices addressing mucositis. 34 Finally, the Release allegedly “materially overstated” the market potential for Mucotrol. 35

The December 1 Release had a dramatic effect on GeoPharma’s stock. That morning, the price zoomed to an all-time high of $11.25 per share, a one-day increase of 153%. 36 Volume was extraordinary as well; 42 million shares changed hands on December 1, against an average daily volume of 22,000 shares. 37

3. Corrective Disclosures

This newfound prosperity did not last even half a day. In response to media inquiries, an FDA spokesperson erroneously stated that the agency had no record of any approval for Mucotrol. 38 After the FDA statement, the price of GeoPharma stock promptly cratered. When trading was halted at approximately 1:30 p.m. on December 1, the stock had fallen to $6.81 per share. 39

The FDA then corrected its misstatement, clarifying that Mucotrol had received marketing approval as a medical device. 40 The next day, GeoPharma issued another press release prior to the opening of the market, intended to address the confusion caused by the December 1 Release. This release stated in pertinent part:

[i]n an earlier press release (July 2004), GeoPharma, Inc. had announced the results of a double blind clinical study of their produc[t] (MF5232, now called Mucotrol™). On December 1, 2004, a press release was issued by the Company after receiving FDA Section 510(k) premarket approval, noting that the FDA approval allows for the marketing of the medical device based on the FDA’s finding of the device being ‘substantially equivalent to legally marketed predicate devices.’ The Company’s application to the FDA requested approval for this prescription device to be approved to be marketed for the mechanical action indicated for the management of pain by soothing oral lesions caused by chemotherapy or radiotherapy mucositis/stomatitis, oral irritations due to oral surgery, braces or dentures in addition to diffusing apthous ulcers. Although it is estimated that approximately 300,000 cancer patients in the U.S. suffer from mucositis, revenues from the Company’s distribution of Mueotrol™ cannot be estimated at this time. 41

On December 2, 2004, GeoPharma shares rose 8.22% to close at $7.37 (at one point reaching an intra-day high of $9.58). 42

After the markets closed on December 2, GeoPharma and two of the individual defendants held a conference call with investors to discuss the December 1 Release. On the call, defendants Mihir Taneja and Sekharam declined to provide a basis for the previous estimate of Mucotrol’s .market potential. 43 Asked why previous company releases referred to development of a drug to treat mucositis, when Mueotrol itself was a device, Sekharam stated that the Company initially tried to develop a drug treatment but ended up with a device. 44

Plaintiffs allege that due to the further disclosures made on the conference call, GeoPharma’s share price fell 12.48% in after-market activity on December 2, closing at $6.45 per share. The shares fell to $5.46 per share the next day. 45

4. Scienter Allegations

Plaintiffs allege that in 2004 GeoPharma embarked on a strategy to “transition [into] a drug manufacturer,” for which “the Company needed to raise substantial capital, which it subsequently did.” 46 To this end, GeoPharma entered into three separate financing arrangements in the Spring of 2004. 47 The terms of each agreement vary, but in brief plaintiffs allege that:

Under the terms of the Company’s financing agreements, Defendants could force a portion of its note holders and preferred shareholders to accept shares of the Company’s common stock in lieu of cash payments if the stock reached a minimum of $7.19 per share for only five consecutive days. From the middle of March 2004, until the start of the Class Period, the price of GeoPharma stock did not trade above the trigger prices for the required period of time. Accordingly, during this time, Defendants [made] expensive monthly cash payments to the Company’s note holders and preferred stock owners. 48

Therefore, defendants “were motivated to engage in the fraudulent scheme ... in order to force the conversion of GeoPharma’s debt and equity financing into common stock (which it would be able to do if the Company’s stock reached certain levels for five consecutive days) in order to avoid making substantial monthly payments on its Term Note and preferred stocks.” 49

Plaintiffs also- allege that defendants knew that the December 1 Release was materially false or misleading:

Defendants knew that the Company had submitted an application to the FDA for approval of a medical device, not a drug, and knew that the FDA had approved Mucotrol as a medical device, not as a drug. Nonetheless, in numerous statements prior to the Class Period, Defendants represented that Mucotrol was a drug and when Defendants announced the FDA approval during the Class Period, they failed to disclose that the approval was for a medical device with a dramatically smaller market than that of a drug. 50

III. LEGAL STANDARD

A. Standard of Review

Under Rule 12(b)(6) of the Federal Rules of Civil Procedure, a motion to dismiss should be granted only if “ ‘it appears beyond doubt that the plaintiff[s] can prove no set of facts in support of [their] claim[s] which would entitle [them] to relief.’ ” 51 The task of the court in ruling on a Rule 12(b)(6) motion is “merely to assess the legal feasibility of the complaint, not to assay the weight of the evidence which might be offered in support thereof.” 52 When deciding a motion to dismiss, courts must accept all factual allegations in the complaint as true, and draw all reasonable inferences in plaintiffs’ favor. 53 Courts generally do not consider matters outside the pleadings but may consider documents attached to the pleadings, documents referenced in the pleadings, or documents that are integral to the pleadings. 54 Courts may also “take judicial notice of well-publicized stock prices without converting the motion to dismiss into a motion for summary judgment.” 55

B. Section 10 and Rule 10b-5

To state a prima facie case for securities fraud under section 10 of the Exchange Act and Rule 10b-5 promulgated thereunder, a plaintiff must allege that “ ‘the defendant, in connection with the purchase or sale of securities, made a materially false statement or omitted a material fact, with scienter, and that plaintiffs reliance on defendant’s action caused injury to the plaintiff.’ ” 56 The requisite state of mind, or scienter, in an action under section 10(b) and Rule 10b-5 is “ ‘an intent to deceive, manipulate or defraud.’ ” 57

Securities fraud actions are subject to the heightened pleading requirements of Federal Rule of Civil Procedure 9(b). 58 A plaintiff alleging securities fraud under section 10(b) and Rule 10b-5 must also satisfy the heightened pleading standards of the Private Securities Litigation Reform Act of 1995 (“PSLRA”). 59 To plead a material misrepresentation or omission under the PSLRA “the complaint [must] specify each statement alleged to have been misleading, the reason or reasons why the statement is misleading, and, if an allegation regarding the statement or omission is made on information or belief, the complaint shall state with particularity all facts on which that belief is formed.” 60 “To meet the pleading standard of Rule 9(b), this Court has repeatedly required, among other things, that the pleading ‘explain why the statements were fraudulent.’ ” 61

1. Actionably False or Misleading Statement

To state a cause of action under section 10(b) and Rule 10b-5, a plaintiff must first plead that defendants made “a false material representation or omitted to disclose material information.” 62 Liability is not restricted only to statements that are literally false: “[s]ome statements, although literally accurate, can become, through their context and manner of presentation, devices which mislead investors. For that reason, the disclosure required by the securities laws is measured not by literal truth, but by the ability of the material to accurately inform rather than mislead prospective buyers.” 63 Therefore, a statement or omission is actionably misleading when a reasonable investor would have been misled. 64 This determination is fact-specific, rarely amenable to disposition as a matter of law. 65

Regarding omissions, generally there can be no liability for an omission under Rule 10b-5 absent a duty to disclose the omitted information. 66 Omissions are actionable only when they cause the statements actually made to be misleading, or if a duty to disclose is created by statute or regulation. 67

2. Scienter

Under the PSLRA, the complaint must “state with particularity facts giving rise to a strong inference that the defen dant acted with the required state of mind.” 68 “Although speculation and eonclusory allegations will not suffice, neither do we require ‘great specificity’ provided the plaintiff alleges enough facts to support ‘a strong inference of fraudulent intent.’ ” 69 Facts giving rise to a strong inference of scienter can be alleged by one of two methods: the plaintiff may plead “motive and opportunity to commit fraud” or “strong circumstantial evidence of conscious misbehavior or recklessness.” 70

i. Motive and Opportunity

“Motive would entail concrete benefits that could be realized by one or more of the false statements.and wrongful non-disclosures alleged,” while “[ojpportunity would entail the means and likely prospect of achieving concrete benefits by the means alleged.” 71 “Motives that are generally possessed by most corporate directors and officers do not suffice; instead, plaintiffs must assert a concrete and personal benefit to the individual defendants resulting from the fraud.” 72 Specifically, insufficient motives include “the desire for the corporation to appear profitable and ... the desire to keep stock prices high to increase officer compensation.” 73 Courts have also rejected as insufficient allegations that a company desired to inflate stock as a method of maintaining its credit rating. 74

On the other hand, the desire “to inflate stock prices while [defendants] sold their own shares” may support a viable claim. 75 Some courts have also found that a company’s desire to inflate its stock price as a prelude to completing a stock-based acquisition of another company can support a scienter inference. 76

Regarding the “opportunity” prong, courts often assume that corporations, corporate officers and corporate directors would have the opportunity to commit fraud if they so desired. 77 However, opportunity to commit fraud may not exist if the alleged scheme had no chance of succeeding. 78

ii. Conscious Misbehavior or Recklessness

When plaintiffs have failed to plead motive and opportunity, “it is still possible to plead scienter by identifying circumstances indicating conscious behavior [or recklessness] by defendant, though the strength of the circumstantial allegations must be correspondingly greater.” 79 Conscious misconduct is relatively easy to identify, “since it encompasses deliberate illegal behavior, such as securities trading by insiders privy to undisclosed and material information ... or knowing sale of a company’s stock at an unwarranted discount.” 80

However, “[r]ecklessness is harder to identify with ... precision and consistency.” 81 To sufficiently allege recklessness, the facts must “approximate an actual intent to aid in the fraud being perpetrated.” 82 Plaintiff must allege facts showing that the defendants’ conduct was “highly unreasonable, representing an extreme departure from the standards of ordinary care to the extent that the danger was either known to the defendant or so obvious that the defendant must have been aware of it.” 83 Recklessness is typically shown in one of two ways; plaintiff must “specifically allege[ ] defendants’ knowledge of facts or access to information contradicting their public statements,” or “allege[ ] facts demonstrating that defendants failed to review or check information that they had a duty to monitor, or ignored obvious signs of fraud.” 84

3. Causation

To maintain a claim for securities fraud, a plaintiff must also plead both (1) that it relied upon defendant’s allegedly fraudulent conduct in purchasing or selling securities, and (ii) that defendant’s conduct caused, at least in part, plaintiffs loss. 85 These two elements are known, respectively, as “transaction causation” and “loss causation.” 86

Loss causation refers to the requirement that a plaintiff demonstrate that the fraudulent scheme caused her loss. 87 In the case of a 10b-5 action alleging a material misstatement or omission, loss causation generally requires a plaintiff to show that her investments would not have lost value if the facts that defendants misrepresented or omitted had been known. 88

A plaintiff cannot satisfactorily allege loss causation simply by alleging that she purchased securities at artificially inflated prices. In Dura Pharmaceuticals, Inc. v. Broudo, 89 the Supreme Court rejected the Ninth Circuit’s permissive pleading standard for loss causation, which required only that a plaintiff allege that she had bought a security at an artificially inflated price. 90 The Court noted that:

[I]t should not prove burdensome for a plaintiff who has suffered an economic loss to provide a defendant with some indication of the loss and the causal connection that the plaintiff has in mind. At the same time, allowing a plaintiff to forgo giving any indication of the economic loss and proximate cause that the plaintiff has in mind would bring about harm of the very sort the statutes seek to avoid. 91

Most recently, the Second Circuit has held that a plaintiff must allege that “the loss be foreseeable and [] the loss be caused by the materialization of the concealed risk.” 92 This Court’s recent decision in In re Initial Public Offering Securities Litigation describes in detail the Second Circuit’s loss causation standard:

Where the alleged misstatement conceals a condition or event which then occurs and causes the plaintiffs loss, it is the materialization of the undisclosed condition or event that causes the loss. By contrast, where the alleged misstatement is an intentionally false opinion, the market will not respond to the truth until the falsity is revealed — i.e. a corrective disclosure. 93

IV. DISCUSSION

A. Plaintiffs Fail to Plead a Cause of Action Against Jugal Taneja

Plaintiffs have sued Jugal Taneja, the Chairman of GeoPharma’s Board of Directors. 94 But plaintiffs do not make any specific allegations against him anywhere in the Complaint. 95 Instead, plaintiffs invoke the “group pleading doctrine,” which allows a plaintiff to rely on “a presumption that statements in ... press releases, or other group-published information, are the collective work of those individuals with direct involvement in the everyday business of the company.” 96

However, this doctrine is “extremely limited in scope, applying only to clearly cognizable corporate insiders with active daily roles in the relevant companies or transactions.” 97 To be sure, the doctrine may apply to outside directors who “although almost by definition [are] excluded from the day-to-day management of a corporation, can fall within the group pleading presumption when, by virtue of their status or a special relationship with the corporation, ... have access to information more akin to a corporate insider.” 98

Plaintiffs fail to allege that Jugal Taneja has a special relationship with GeoPharma. A bare allegation that Jugal Taneja is Chairman of the Board, in the absence of any specific allegation that he played a role in the preparation of the December 1 Release, or otherwise took part in the day-to-day operations of GeoPharma, does not justify applying the group pleading doctrine. 99 Therefore, all claims against him are dismissed. 100

B. Actionably Misleading Statements

Plaintiffs allege three distinct misstatements in the December 1 Release. First, plaintiffs allege that the statement that GeoPharma “received approval from the [FDA] for Mucotrol, a prescription product for the management of oral mucositis/stomatitis” is misleading because it failed to specify that, despite GeoPharma’s earlier statements, Mucotrol was approved as a medical device and not as a drug. 101 Second, the Release allegedly “materially overstated” the market potential for Mucotrol. 102 Third, plaintiffs allege that GeoPharma had a duty to disclose that Mucotrol had existing competition in the field of medical devices. 103

I. Mucotrol as a “Prescription Product”

Defendants first note that plaintiffs cannot allege that the description of Mucotrol as a “prescription product” is literally false. 104 After all, Mucotrol is in fact a product available by prescription. 105 But plaintiffs actually allege that the term “prescription product” in the December 1 Release could be interpreted by a reasonable investor as referring to a new drug, given the context created by defendants’ earlier statements concerning GeoPharma’s ongoing development of a new drug to treat mucositis, as well as the context of the rest of the December 1 Release, which spoke of a vast market potential for Mucotrol more consistent with a new drug than a new medical device. 106

Defendants’ argument that the December 1 Release’s reference to a “prescription product” was not misleading reduces to the proposition that a reasonable investor would have understood the December 1 Release as an update of earlier GeoPharma statements which had referred to Mucotrol as a drug. In particular, defendants make much of the fact that the December 1 Release describes Mucotrol as a product that “manages” mucositis — a verb that to a reasonable investor should denote a medical device, as opposed to a drug that “treats” a disease. 107 Therefore, defendants argue that a reasonable investor could not be misled by the December 1 Release into thinking that GeoPharma had gained approval of a new drug, because such an investor would necessarily “have to recognize that the December 1 Press Release, in the most significant way, was not consistent with the earlier statements about Mucotrol.” 108

This case is similar to In re Ribozyme Pharmaceutical, Inc. Securities Litigation, a case on which plaintiffs rely. 109 In that case, a drug company defendant announced that a drug it was developing had entered Phase II clinical trials. 110 Defendant subsequently issued a media advisory claiming that the same drug had “[made] cancer drug history,” and asserting that the drug had taken “an important step forward,” “making both clinical history and industry news.” 111

After this media advisory, the company’s stock doubled in less than two hours. 112 But after trading was halted, defendants disclosed that the media advisory merely referred to the previously-disclosed commencement of Phase II trials. 113 At the motion to dismiss stage, the court accepted plaintiffs’ argument that this media advisory could be actionably misleading; in light of defendants’ earlier announcements it was reasonable to interpret the advisory as announcing additional progress beyond the previously-disclosed Phase II trials. 114

Defendants are correct that a company is not required to use the clearest language possible in its public statements. 115 Even so, a reasonable investor could have been misled by failing to absorb the fíne distinction between the terms “drug” and “prescription product.” 116 Therefore, plaintiffs have properly alleged that the use of a rather vague term such as “prescription product” in the December 1 Release, given the context of GeoPharma’s previous statements, could be objectively misleading.

2. Statement of “Market Potential”

The December 1 Release contained the following statement:

Mucositis afflicts approximately 40% of patients receiving cancer chemotherapy and 75% of bone marrow transplant recipients as well as 100% of patients receiving radiotherapy for cancer of the head and neck. It is estimated that approximately 300,000 cancer patients in the U.S. suffer from mucositis associated with cancer treatments. Based on this, the estimated U.S. oncology market potential for Mucotrol sales are between $75 million and $800 million per annum and the estimated global market is between $250 million and $1 billion per annum. 117

Defendants argue that the statement is not actionable because it qualifies for the protection of the PSLRA’s safe-harbor for forward-looking statements. 118 This safe harbor protects forward-looking statements if one of three conditions are met: 1) the forward-looking statement is identified as such and accompanied by “meaningful cautionary statements identifying important factors that could cause actual results to differ materially from those in the forward-looking statement;” 2) the statement is “immaterial”; or 3) the plaintiff fails to prove that the statement was made with actual knowledge that the statement was false or misleading. 119

Fairly read as a statement of potential revenues Mucotrol might garner, the market potential statement qualifies as a forward-looking statement under the PSLRA, thereby warranting protection as long as it meets one of the three statutory conditions . 120 Neither of the first two conditions are met. 121 But, for the reasons discussed later in this Opinion, plaintiffs have failed to plead that defendants had actual knowledge that the market potential statement was false. 122

Plaintiffs attempt to avoid the PSLRA safe harbor by characterizing the market potential statement as a statement of historical fact. “At any point in time the ‘market potential’ of a product is a fixed number — whether or not knowable with certainty.” 123 But if the market potential statement is not a revenue projection for Mucotrol, then it could only be interpreted as an estimate of the total market for all products that treat or manage mucositis, whether or not the products are manufactured by GeoPharma. If this is the case, plaintiffs have not pled that the statement is false. As defendants note, “given the number of people who suffer from mucositis, as set forth in the December 1 Press Release, it is entirely reasonable to assume that there is at least $75 million out in the market to be spent on products addressing the affliction.” 124 The statement is either a protected forward-looking statement, or it is a statement of historical fact that is not alleged to be false. Either way, for the reasons set forth more fully below, the market potential statement is not actionable.

3. Non-Disclosure of Competitors’ Products

Plaintiffs assert that, in light of earlier company statements in connection with Mucotrol to the effect that no effective treatment for mucositis is available, GeoPharma had a duty to disclose competitor products as a part of its general duty to update statements that may have become misleading as a result of intervening events. 125 But plaintiffs are not claiming that those earlier statements are false, and there is normally no duty to disclose the existence of competitors. 126 At most, as plaintiffs themselves recognize, the failure to disclose the existence of competition is not a separate misstatement or omission, but merely an example of how defendants could have worded the December 1 Release differently so as to avoid misleading investors on the central issue of whether Mucotrol was a drug or a medical device. 127 Therefore, this alleged omission is not actionable.

C. Scienter

While plaintiffs have adequately alleged that the December 1 Release’s description of Mucotrol as a “prescription product” could be objectively misleading, “a statement does not become actionable simply by virtue of being false (or otherwise misleading), — the other elements of fraud, such as scienter and reliance, must also be present.” 128 For the following reasons, plaintiffs’ allegations must be dismissed because they have failed to “giv[e] rise to a strong inference that the defendant acted with the required state of mind.” 129

1. Motive and Opportunity

a. GeoPharma

Plaintiffs allege that GeoPharma’s motive to inflate its share price was to force some of its noteholders and preferred shareholders to accept shares of its common stock, so GeoPharma could avoid making principal, interest and dividend payments pursuant to those financing arrangements. 130 GeoPharma could accomplish this if its stock traded above certain levels for either five or ten days, depending on the particular security purchase agreement in question. 131 In short, plaintiffs allege that “[defendants embarked on a scheme which would enable them to reduce the Company’s monthly cash payments [for interest on the notes].” 132 These allegations are insufficient for a fundamental reason — the alleged scheme could not possibly have succeeded. 133 The FDA. approval of Mucotrol was public information, and it would have been obvious ex ante to defendants that financial reporters and/or analysts would contact the FDA immediately after the December 1 Release (which is of course what occurred). 134 There was never the slightest chance that GeoPharma stock could be inflated by the December 1 Release for anywhere close to the five days needed to carry out the alleged scheme, and therefore plaintiffs cannot raise a strong inference of scienter on this basis.

Plaintiffs’ motive allegations fail for another reason — courts in this Circuit have consistently held that allegations that a defendant was motivated to commit securities fraud by a desire to reduce its debt burden, or otherwise reduce borrowing costs, are insufficient to raise a scienter inference. 135 Plaintiffs’ allegations that GeoPharma sought to reduce its cash outlays for debt service fall squarely into this category. 136

Plaintiffs argue that the desire to inflate the stock to activate the conversion feature of GeoPharma’s financing agreements is a valid motive because it represents a “specific corporate transaction,” citing cases where- a company’s desire to make a corporate acquisition with inflated stock was held to be a valid motive for scienter purposes. 137 But plaintiffs read these cases too broadly — they are in fact limited to the desire to carry out corporate acquisi tions, 138 The Second Circuit has explained that the motive to acquire another company can support an inference of scienter because, unlike the motive to reduce borrowing costs, it is a motive not generally possessed by all corporations. 139 Plaintiffs fail to offer any convincing reason why the short-term or unusual nature of the debt arrangement in this case merits departure from the San Leandro rule. 140

b. Individual Defendants

There are no motive and opportunity allegations against the individual defendants. Typically, a plaintiff alleges that an individual traded in company stock after the stock was artificially inflated as a result of the scheme. 141 No such allegations are made in this case against any individual defendant. 142 For that matter, there are no allegations explaining how any of the individual defendants personally profited from the alleged scheme. 143 Moreover, a corporate motive (such as the desire to activate the conversion features of the securities purchase agreements) cannot be ascribed to individual defendants. 144 Therefore, plaintiffs have not alleged scienter against the individual defendants through motive and opportunity.

2. Conscious Misbehavior/Recklessness

Defendants argue, in their reply brief, that because the alleged scheme could not have succeeded, this alone precludes a finding of the required strong inference of scienter, even when plaintiffs attempt to prove scienter by alleging conscious misbehavior or recklessness. 145 Defendants’ novel argument has merit. 146 Conscious misbehavior is an intentional wrongful act. Surely if such alleged mis behavior is incapable of defrauding investors, that, in itself, negates the inference of intent to defraud. 147 The same must be true for allegations of reckless conduct. Reckless acts are highly unreasonable, representing an extreme departure from the standards of ordinary care. If the alleged reckless behavior is incapable of defrauding investors, that, too, negates any inference of intent to defraud.

In any case, plaintiffs’ allegations of conscious misbehavior or recklessness fall far short of the required standard. 148 Plaintiffs allege that defendants were at least reckless in issuing the December 1 Release, because defendants knew that the FDA approval was for a medical device, not a drug. 149 “When the December 1, 2004 press release was issued, Defendants knew or were extremely reckless in not knowing that they were misrepresenting ■ material facts related to the corporation.” 150 But even if the FDA approval letter could be said to have contradicted the December 1 Release in some sense, the FDA approval of Mucotrol was public information. Plaintiffs have cited no case, and I am aware of none, where a plaintiff adequately pled scienter based solely on the contradiction between public information and the company’s public statements. 151 Cases in this Circuit assume that the contradictory information in question must be non-public. 152 Especially in light of plaintiffs’ failure to put forward a plausible motive for the alleged scheme, I cannot conclude that defendants’ statements, even though confusingly worded, exhibited “an extreme departure from the standards of ordinary care” necessary to support an inference of scienter. 153

D. Loss Causation 154

Defendants also dispute plaintiffs’ allegations of loss causation. First, defendants note that GeoPharma’s stock price actually increased after the alleged corrective disclosures (the December 2 Press Release and the December 2 conference call), reaching a high at one point of $9.58. 155 Second, defendants argue that any artificial inflation during the class period cannot be attributed to GeoPharma’s alleged misstatements, as opposed to other possible causes such as the incorrect news reports by Reuters and Dow Jones on the morning of December 1 that GeoPharma had gained approval of a “drug”. 156

Leaving aside for the moment that plaintiffs have failed to adequately allege scienter, their loss causation allegations are sufficient. Defendants overstate the nature of plaintiffs’ burden at this stage of the proceedings when they argue that plaintiffs must exclude all other possible causes of the artificial inflation. 157 To the contrary, plaintiffs must only allege a false or misleading statement, 158 which caused an artificial inflation of the stock, 159 followed by a dissipation of that inflation after corrective disclosures were made. 160 The corrective disclosure in this case involved the correction of the misapprehension, fostered by the December 1 Release, that GeoPharma had gained approval of a new drug instead of a new medical device. Therefore, the Complaint puts defendants on sufficient notice of the “causal connection that the plaintiff has in mind.” 161

E. Section 20(a)

Plaintiffs also bring allegations against the individual defendants under section 20(a) of the Exchange Act. 162 However, a primary violation of section 10(b) is a prerequisite to finding control person liability under section 20(a). 163 Accordingly, as plaintiffs have failed to adequately plead scienter, the control person allegations are dismissed.

F. Leave to Amend

Plaintiffs have requested leave to amend the Complaint in the event of dismissal. 164 Pursuant to Rule 15(a), leave to amend a complaint “shall be freely freely granted when justice so requires.” 165 Moreover, “[i]t is the usual practice upon granting a motion to dismiss to allow leave to re-plead.” 166 Plaintiffs are therefore granted leave to replead within twenty days of this Opinion and Order.

V. CONCLUSION

For the foregoing reasons, defendants’ motion to dismiss is granted, without prejudice, with leave to replead within twenty days of receipt of this Opinion and Order. The Clerk is directed to close this motion [Docket # 40],

SO ORDERED:

1 . 15 U.S.C. §§ 78j(b), 78t(a); 17 C.F.R. § 240.10(b)(5).

2 . See generally Memorandum of Law in Support of Defendants' Motion to Dismiss the Consolidated Class Action Complaint ("Def.Mem.”).

3 .See Consolidated Amended Class Action Complaint for Violations of Federal Securities Laws ("Complaint”) ¶ 5. The lead plaintiffs are Mike Moshayedi, Hung Van Luong, Joseph Adevai, Guy Shilling and Scott M. Syring. See id.; see also Order Dated March 9, 2005 (appointing lead plaintiffs).

4 . Complaint ¶ 1.

5 . See id. ¶ 21.

6 . See id. ¶ 6. GeoPharma also includes another unit, Innovative Health Products, that develops and manufactures nutritional supplements. See id.

7 . See id. ¶ 7(c).

8 . See id. ¶ 7(b).

9 . See id. ¶ 7(a). The Complaint does not otherwise refer specifically to Jugal Taneja.

10 . See id. ¶¶ 7(a), (b), (c).

11 . See id. ¶¶ 33-37.

12 . See id. ¶ 33.

13 . Id. ¶ 34 (quotation omitted).

14 . Id. ¶ 34.

15 . See id. ¶ 36.

16 . Id. ¶ 36.

17

18 . See Complaint ¶ 36.

19 . The Complaint does not define this term, but a 510(k) application is a premarketing submission to the FDA, seeking to demonstrate that the device to be marketed is substantially equivalent to legally marketed devices that are not subject to FDA premarket approval for one of several reasons. See Premarket Notification, at http://www.fda.gov/ cdrb/devadvice/314.html.

20 . See Complaint ¶ 40. The submission listed defendant Sekharam as the company contact for the application. See id.

21 . See id. ¶ 40.

22 . See generally Complaint Ex. B.

23 . See id. ¶ 41; id. Ex. B; see also supra note 19.

24 . See id. ¶ 42.

25 . See id. ¶ 43.

26 . See id. ¶¶ 43-44.

27

28 . See id.

29 . See id. ¶ 47.

30 . Id. (emphasis added).

31 . Id.

32 . See id. ¶¶ 47-49.

33 . See id. ¶ 49(a).

34 . See id. ¶ 49(b). Specifically, plaintiffs allege that GeoPharma should have disclosed that "Mucotrol was in direct competition with at least two other products which had been in the market for an extended period of time— Sinclair Pharmaceuticals’ Gelclair Concentrated Oral Gel and Carrington Labs’ RadiaCare Oral Wound Rinse.” Id.

35 . See id. ¶¶ 49(c), (d).

36 . See id. ¶ 48.

37

38 . See id. ¶ 50 (emphasis added).

39

40

41 . Id. ¶51.

42 . See id. V 52.

43 . See id. ¶ 53.

44 . See id. ¶ 54.

45 . See zd. ¶ 53.

46 . Id. ¶ 24; see also id. ¶¶ 23, 37-38 (discussing the Company’s plan to focus more on generic drug manufacture going forward). Plaintiffs allege that GeoPharma began 2004 with "only” $920,500 in cash, an amount that they imply was insufficient to achieve its goals. See id. ¶ 24.

47 .See id. ¶¶ 25-32.

48 . Id. ¶ 32. Each of the three financing arrangements had different standards for when GeoPharma could exercise the conversion feature. See id. ¶ 30 (term note, convertible into common stock if that stock trades higher than $7.19/share for five consecutive trading days); id. ¶ 27 (warrants, convertible if stock trades higher than $7.26/share for five consecutive trading days); id ¶ 29 (preferred stock, convertible if stock trades at an average higher than $15/share for ten consecutive trading days).

49 . Id. ¶ 62.

50 . Id. ¶ 61 (emphasis in original).

51 . Weixel v. Board of Educ. of City of New York, 287 F.3d 138, 145 (2d Cir.2002) (quoting Conley v. Gibson, 355 U.S. 41, 45-46, 78 S.Ct 99, 2 L.Ed.2d 80 (1957)).

52 . Levitt v. Bear Steams & Co., Inc., 340 F.3d 94, 101 (2d Cir.2003) (quotation marks and citations omitted).

53 . See Chambers v. Time Warner Inc., 282 F.3d 147, 152 (2d Cir.2002).

54 . See id. at 152-53; see also In re Initial Public Offering Sec. Litig., 241 F.Supp.2d 281, 331 (S.D.N.Y.2003).

55 . Ganino v. Citizens Utilities Co., 228 F.3d 154, 167 n. 8 (2d Cir.2000) (citing cases). Accord In re AOL Time Warner, Inc. Sec. and ERISA Litig., No. 02 Civ. 5575, 2004 WL 992991, at *38 n. 61 (S.D.N.Y. May 5, 2004).

56 . Lawrence v. Cohn, 325 F.3d 141, 147 (2d Cir.2003) (quoting Ganino, 228 F.3d at 161 (citing cases)).

57 . Ganino, 228 F.3d at 168 (quoting Ernst & Ernst v. Hochfelder, 425 U.S. 185, 193 n. 12, 96 S.Ct. 1375, 47 L.Ed.2d 668 (1976)).

58 . Rule 9(b) provides that ”[i]n all averments of fraud or mistake, the circumstances concerning fraud and mistake shall be stated with particularity. Malice, intent, knowledge and other condition of mind may be averred generally.” See also In re Scholastic Corp. Sec. Litig., 252 F.3d 63, 69-70 (2d Cir.2001) (applying Rule 9(b) standard to securities fraud claims).

59 . Pub.L. No. 104-67, 109 Stat. 737 (1995). See Novak v. Kasaks, 216 F.3d 300, 306 (2d Cir.2000).

60 . 15 U.S.C. § 78u-4(b)(1)(B).

61 . Rombach v. Chang, 355 F.3d 164, 172 (2d Cir.2004) (quoting Mills v. Polar Molecular Corp., 12 F.3d 1170, 1175 (2d Cir.1993)).

62 . Acito v. IMCERA Group, Inc., 47 F.3d 47, 52 (2d Cir.1995).

63 . McMahan & Co. v. Wherehouse Entm’t, Inc., 900 F.2d 576, 579 (2d Cir.1990). Accord High View Fund, L.P. v. Hall, 27 F.Supp.2d 420, 425 (S.D.N.Y.1998) ("the central issue ... is not whether the particular statements taken separately, were literally true, but whether defendants’ representations, taken together and in context, would have misl[ed] a reasonable investor about the nature of the [securities].”) (alterations in original; quotation and citation omitted).

64 . See McMahan & Co., 900 F.2d at 579; see also Fogarazzo v. Lehman Bros., 341 F.Supp.2d 274, 292 (S.D.N.Y.2004) (among the requirements to sustain a 10b-5 claim is that defendant made a statement that was "objectively misleading”).

65 . Cf. Wertheim Schroder & Co. v. Avon Prods., Inc., No. 91 Civ. 2287, 1993 WL 126427, at *15 (S.D.N.Y. Apr.l, 1993) (denying defendant summary judgment because plaintiff created a genuine issue of fact on the issue of whether defendants’ statements were misleading even if literally true).

66 . See Basic, Inc. v. Levinson, 485 U.S. 224, 239 n. 17, 108 S.Ct. 978, 99 L.Ed.2d 194 (1988); see also In re Time Warner Inc. Sec. Litig., 9 F.3d 259, 267 (2d Cir.1993).

67 . See Glazer v. Formica Corp., 964 F.2d 149, 157 (2d Cir.1992); see also Robbins v. Moore Med. Corp., 894 F.Supp. 661, 668 (S.D.N.Y. 1995).

68 . 15 U.S.C. § 78u-4(b)(2).

69 . Ganino, 228 F.3d at 169 (quoting Stevelman v. Alias Research Inc., 174 F.3d 79, 84 (2d Cir.1999)).

70 . Kalnit v. Eichler, 264 F.3d 131, 138 (2d Cir.2001) (quotation and citation omitted). Accord Novak, 216F.3dat311.

71 . Shields v. Citytrust Bancorp, Inc., 25 F.3d 1124, 1130 (2d Cir.1994).

72 . Kalnit, 264 F.3d at 139.

73 . Id. Accord Acito, 47 F.3d at 54 (“Plaintiffs' allegation that defendants were motivated to defraud the public because an inflated stock price would increase their compensation is without merit. If scienter could be pleaded on that basis alone, virtually every company in the United States that experiences a downturn in stock price could be forced to defend securities fraud actions”). Similarly, it is insufficient to allege that defendants desired to protect their executive compensation and the prestige they enjoyed as corporate officers. See Shields, 25 F.3d at 1130.

74 . See San Leandro Emergency Med. Group Profit Sharing Plan v. Philip Mortis Cos., 75 F.3d 801, 814 (2d Cir.1996).

75 . Kalnit, 264 F.3d at 139. Accord Novak, 216 F.3d at 307 (same); Shields, 25 F.3d at 1128 (same). "Insider sales may serve as evidence of motive, but the plaintiff must allege that any such sales were unusual in some way.” In re Interpublic Sec. Litig., No. 02 Civ. 6527, 2003 WL 21250682, at *11 (S.D.N.Y. May 29, 2003). For example, sales could be unusual because they were extensive, and the amount of profit and the percentage of a defendant’s holdings that were sold are also relevant to this inquiry. See In re Worldcom, Inc. Sec. Litig., 294 F.Supp.2d 392, 412 (S.D.N.Y.2003).

76 . See Rothman v. Gregor, 220 F.3d 81, 94 (2d Cir.2000) (allegations that defendants inflated stock price with any eye towards acquiring another company helped support scienter inference, although court declined to decide whether such an allegation could support a scienter inference by itself); In re Vivendi Universal, S.A. Sec. Litig., 381 F.Supp.2d 158, 185 (S.D.N.Y.2003) ("[s]cienter may be imputed, as is the case here, to defendants when defendants were motivated to inflate company stock prices as a means to effectuate a specific acquisition that would not otherwise be possible without fraudulently inflating stock prices”).

77 . See In re Time Warner Sec. Litig., 9 F.3d at 269 (assuming that defendants had opportunity to manipulate their company’s stock); see also Kalnit v. Eichler, 99 F.Supp.2d 327, 335 (S.D.N.Y.2000) (same); High View Fund, L.P., 27 F.Supp.2d at 427 (same).

78 . See Shields, 25 F.3d at 1120 (the complaint "fails to allege a sufficient opportunity to derive a benefit from the alleged misstatements and nondisclosures: the ordinary course of bank business would lead to [discovery of the misstatements], as it did”).

79 . Kalnit, 264 F.3d at 142 (quotation and citation omitted).

80 . Novak, 216 F.3d at 308 (citation omitted).

81

82 . Chill v. General Elec. Co., 101 F.3d 263, 269 (2d Cir.1996) (quotation and citation omitted).

83 . Rothman, 220 F.3d at 90 (citing Novak, 216 F.3d at 308). The Second Circuit has also noted that "[a]n egregious refusal to see the obvious, or to investigate the doubtful, may in some cases give rise to an inference of ... recklessness.” Chill, 101 F.3d at 269 (quotation and citation omitted).

84 . Novak, 216 F.3d at 308.

85 . See Castellano v. Young & Rubicam, Inc., 257 F.3d 171, 179 (2d Cir.2001).

86 . "Transaction causation is generally understood as reliance.” Id. at 186. A rebuttable presumption of transaction causation may be established under the "fraud on the market” theory, even where a plaintiff was unaware of the fraudulent conduct at the time of the purchase or sale:

'The fraud on the market theory is based on the hypothesis that, in an open and developed securities market, the price of a com pany’s stock is determined by the available material information regarding the company and its business.... Misleading statements will therefore defraud purchasers of stock even if the purchasers do not directly rely on the misstatements.... The causal connection between the defendants’ fraud and the plaintiffs’ purchase of stock in such a case is no less significant than in a case of direct reliance on misrepresentations.'

Basic, Inc., 485 U.S. at 241-42, 108 S.Ct. 978 (alterations in original) (quoting Peil v. Speiser, 806 F.2d 1154, 1160-61 (3d Cir.1986)).

Pleading that defendants perpetrated a fraud on the market, therefore, fulfills a plaintiff's transaction causation pleading requirement.

87 .See Marbury Mgmt., Inc. v. Kohn, 629 F.2d 705, 716-17 (2d Cir.1980) (Meskill, J„ dissenting) (noting that "a fundamental principle of causation which has long prevailed under the common law of fraud and which has been applied to comparable claims brought under the federal securities acts ... is, quite simply, that the injury averred must proceed directly from the wrong alleged and must not be attributable to some supervening cause.”). In 1995, Congress codified the loss causation requirement in the PSLRA:

In any private action arising under this chapter, the plaintiff shall have the burden of proving that the act or omission of the defendant alleged to violate this chapter caused the loss for which the plaintiff seeks to recover damages.

15 U.S.C. § 78u-4(b)(4).

88 . See, e.g., Suez Equity Investors, L.P. v. Toronto-Dominion Bank, 250 F.3d 87, 96 (2d Cir.2001).

89 .-U.S.-, 125 S.Ct. 1627, 1630, 161 L.Ed.2d 577 (2005).

90 . See Broudo v. Dura Phaims., Inc., 339 F.3d 933, 938 (9th Cir.2003).

91 . Dura, 125 S.Ct. at 1634.

92 . Lentell v. Merrill Lynch & Co., 396 F.3d 161, 173 (2d Cir.2005) (emphasis omitted).

93 . No. 21 MC 92, 2005 WL 1529659, at *6 (S.D.N.Y. June 28, 2005) (citations omitted).

94 . See Complaint ¶ 7(a).

95 . For that matter, Jugal Taneja is not mentioned at all in the Complaint except to name him as a defendant. It is clear that a mention of "defendant Taneja” at Complaint ¶ 53 refers to Mihir Taneja.

96 . In re Oxford Health Plans, Inc., 187 F.R.D. 133, 142 (S.D.N.Y. 1999) (quotation and citation omitted).

97 . Polar Int’l Brokerage Corp. v. Reeve, 108 F.Supp.2d 225, 237 (S.D.N.Y.2000).

98 . In re Independent Energy Holdings PLC Sec. Litig., 154 F.Supp.2d 741, 767-68 (S.D.N.Y.2001), abrogated on other grounds by In re Initial Public Offering Sec. Litig., 241 F.Supp.2d at 352 (discussing pleading standard for claims under section 15 of the Securities Act).

99 . See Dresner v. Utility.com, Inc., 371 F.Supp.2d 476, 493-94 (S.D.N.Y.2005) (allegations against "non-insider” defendants fail to satisfy Rule 9(b) when there is no specific allegation to suggest that those defendants "took part in the preparation” of misstatements at issue, nor any allegation that non-insider defendants "acted like corporate insiders”); cf. Shanahan v. Vallat, No. 03 Civ. 3496, 2004 WL 2937805, at *4 (S.D.N.Y. Dec. 19, 2004) (defendant Chairman of the Board within group pleading doctrine because plaintiffs sufficiently pled that he was involved in the everyday business of defendant company); In re Independent Energy Holdings, 154 F.Supp.2d at 768 (citation omitted) (group pleading doctrine covers an outside director who as "a founder of the Company and its largest individual shareholder ... may be able to influence the company”).

100 .Plaintiffs’ opposition brief offers additional facts concerning Jugal Taneja in an attempt to justify application of the group pleading doctrine. See Lead Plaintiffs’ Opposition to Defendants’ Motion to Dismiss the Consolidated Amended Class Action Complaint ("PI. Opp.”) at 23 n. 18 (asserting that Jugal Taneja is a large GeoPharma shareholder; is the father of defendant Mihir Taneja; and signed a form 10-K referenced in the Complaint); but see id. at 22-23 ("Plaintiffs submit that [the allegations in the Complaint] alone are sufficient to apply the group pleading doctrine to Jugal Taneja.”) However, none of these new facts appear in the Complaint, which cannot be amended by the brief in opposition to a motion to dismiss. See, e.g., In re Livent, Inc. Noteholders Sec. Litig., 151 F.Supp.2d 371, 432 (S.D.N.Y.2001).

In any case, it is unlikely that these new facts would establish that Jugal Taneja had a hand in the preparation of the December 1 Release, see Dresner, 371 F.Supp.2d at 493-94, or had a special relationship with GeoPharma giving rise to an inference that he had access to information akin to a corporate insider, see In re Independent Energy Holdings, 154 F.Supp.2d at 767-68.

101 . See Complaint ¶ 49(a).

102

103 . See id. ¶ 49(b).

104 . See Def. Mem. at 7.

105 . See Complaint Ex. B (attachment to the FDA's 501 (k) approval letter indicates that Mucotrol is for "PRESCRIPTION USE”).

106 . See id. ¶¶ 34, 36, 49(a), 61; PI. Opp. at 8-II.

107 . See Def. Mem. at 8. In fact, defendants note that even plaintiffs’ Complaint explains that the salient difference between a "drug” and a "medical device” is that the former "treats” while the latter only "manages.” Id. (citing Complaint ¶¶ 43, 46, 49(a)).

108 . Reply Memorandum of Law in Further Support of Defendants’ Motion to Dismiss the Consolidated Class Action Complaint ("Reply Mem.”) at 6.

109 . 119 F.Supp.2d 1156 (D.Colo.2000); see also Pl. Mem. at 9-10 (discussing In re Ribozyme ).

110 . See In re Ribozyme, 119 F.Supp.2d at 1160.

111

112

113

114 . See id. at 1162.

115 . See Def. Mem. at 8 ("[wjhile plaintiffs may have preferred that the Company had used different language — describing Mucotrol as a 'medical device’, for example — this preference does not transform an accurate description into a misleading one”); see also Tuchman v. DSC Communications Corp., 14 F.3d 1061, 1069 (5th Cir.1994) (defendants who described a contract as a "particular success” under no duty to use a different adjective that plaintiffs asserted would be more accurate); cf. In re American Express Sec. Litig., No. 02 Civ. 5533, 2004 WL 632750, at *9 (S.D.N.Y. Mar.31, 2004) ("where a defendant fully discloses the material facts, plaintiffs cannot predicate a Rule 10b-5 claim on the defendant's failure to disclose those facts in critical terms.”).

116 . See Halperin v. eBanker USA.com, Inc., 295 F.3d 352, 359 (2d Cir.2002) ("a claim fails to state a claim of securities fraud if no reasonable investor could have been misled about the nature of the risk when he invested.”) (emphasis in original); cf. Virginia Bankshares v. Sandberg, 501 U.S. 1083, 1097, 111 S.Ct. 2749, 115 L.Ed.2d 929 (1991) ("If it would take a[n] ... analyst to spot the tension between [a true statement and a deceptive one], whatever is misleading will remain materially so, and liability should follow ... [t]he point of a proxy statement, after all, should be to inform, not to challenge the reader’s critical wits.”).

117 . Complaint ¶ 47 (emphasis added).

118 . See Def. Mem. at 12-13. Defendants also argue that the statement is a general expression of optimism, immaterial as a matter of law. Id. at 11.

119 . See 15 U.S.C. § 78u-5(c)(l).

120 . See 15 U.S.C. § 78u-5(i)(l)(A) (the term forward-looking statement means, inter alia, “a statement containing a projection of revenues, income (including income loss), earnings (including earnings loss) per share, capital expenditures, dividends, capital structure, or other financial items”).

121 . The market potential statement is clearly material, and plaintiffs are correct that the cautionary language present in the December 1 Release was mere boilerplate that did not convey "substantive information about factors that realistically could cause results to differ materially from those projected.” PL Opp. at 14 (quotation and citation omitted).

122 . See infra Section IV.C.2 (discussing whether plaintiffs acted with conscious knowledge or recklessness that their statements were false). See also High View Fund, L.P., 27 F.Supp.2d at 427 n. 3 (holding that when plaintiffs fail to plead scienter, there is no need to determine whether plaintiffs have met the “marginally higher” standard for pleading actual knowledge of the falsity of a forward-looking statement under the PSLRA).

123 . PL Opp. at 13.

124 . Reply Mem. at 8-9.

125 . See Pl. Opp. at 16.

126 . See Castillo v. Dean Witter Discover & Co., No. 97 Civ. 1272, 1998 WL 342050, at *8 (S.D.N.Y. June 25, 1998); see also In re Donald J. Trump Casino Sec. Litig., 7 F.3d 357, 375-76 (3d Cir.1993) ("[t]he federal securities laws do not ordain that the issuer of a security compare itself in myriad ways to its competitors, whether favorably or unfavorably”).

127 . See Pl. Opp. at 16 (“Had Defendants disclosed [Mucotrol’s] competitors ... investors would have some notice that, among other things: (i) Mucotrol was really a device and not a new revolutionary drug; (ii) its market potential, as estimated by GeoPharma, had no reasonable basis in fact, and (iii) its potential sales were limited and could best be estimated by looking to its established competition.”).

128 . Fogarazzo, 341 F.Supp.2d at 294.

129

130 . See Complaint ¶¶ 33, 62.

131 . See id. ¶¶ 27, 29-30, 32; see also supra notes 47-49 and accompanying text.

132 . Id. ¶ 33; see also id. ¶ 62 ("[djefendants were motivated to engage in the fraudulent scheme detailed herein in order to force the conversion of GeoPharma's debt and equity financing into common stock ... in order to avoid making substantial monthly payments on its Term Note and preferred stocks”).

133 . It is a bit unclear whether patent impossibility of the alleged scheme goes to the "motive” or the "opportunity” prong. See In re Time Warner Inc. Sec. Litig., 794 F.Supp. 1252, 1260 (S.D.N.Y.1992), rev’d on other grounds, 9 F.3d 259 (2d Cir.1993) (emphasis added) (no motive for committing fraud when alleged scheme “could not rationally have been expected to succeed”); but see Shields, 25 F.3d at 1130 (emphasis added) (the com plaint "fails to allege a sufficient opportunity to derive a benefit from the alleged misstatements and nondisclosures: the ordinary course of bank business would lead to [discovery of the misstatements], as it did”).

134 . See Complaint ¶¶ 50. In White v. H.R. Block, Inc., plaintiffs alleged that defendants misled investors by concealing the pendency of twenty large class-action lawsuits against defendants, "by either silence or anodyne references [to the litigation] in Block's public filings and press releases.” No. 02 Civ. 8965, 2004 WL 1698628, at *8 (S.D.N.Y. July 28, 2004). The court found that plaintiffs had not pled opportunity as, given the "trove” of public information on the litigation independently available, the "prospect of achieving concrete benefits by the means alleged” was far from "likely.” Id.

135 . See, e.g., San Leandro, 75 F.3d at 814 (rejecting motive allegations based on theory that an inflated stock price would maximize marketability of debt securities issued during class period: "We do not agree that a company's desire to maintain a high bond or credit rating qualifies as a sufficient motive for fraud in these circumstances, because [i]f scienter could be pleaded on that basis alone, virtually every .company in the United States that experiences a downturn in stock price could be forced to defend securities fraud actions.") (quotation and citation omitted).

136 . See In re Duane Reade Inc. Sec. Litig., No. 02 Civ. 6478, 2003 WL 22801416, at *8-9 (S.D.N.Y. Nov.25, 2003) (rejecting motive allegations based on company’s desire to inflate stock in order to pay down debt); see also Leventhal v. Tow, 48 F.Supp.2d 104, 115 (D.Conn.1999) (rejecting motive allegations based on company's desire to inflate stock to get more favorable terms on certain stock-for-stock transactions and in the issuance of debentures).

137 . PL Mem. at 20-21.

138 . See Rothman, 220 F.3d at 93 (allegation that company used inflated stock price to make it less costly to acquire another company); In re Time Warner Inc. Sec. Litig., 9 F.3d at 269-70 (allegation that defendants wanted to lessen dilutive effect of upcoming offering, and avoid jeopardizing talks with potential strategic alliance partners); In re Vivendi Universal, S.A., Sec. Litig., 381 F.Supp.2d at 185 (allegation that defendant wanted to use inflated stock to "acquire and continue acquiring” several companies); Burstyn v. Worldwide Xceed Group, Inc., No. 01 Civ. 1125, 2002 WL 31191741, at *5 (S.D.N.Y. Sept. 30, 2002) (allegation that defendants’ specific goal was to acquire companies).

One court has defined this "specific acquisition” rule more broadly. In re Complete Mgmt. Inc. Sec. Litig., 153 F.Supp.2d 314, 328 (S.D.N.Y.2001) (emphasis added) ("the artificial inflation of a stock price in order to achieve some more specific goal may satisfy the pleading requirement”). However, even in that case defendant's "specific goal” was to inflate its stock price to use it as currency for acquisitions. See id. at 327-28.

139 . See Rothman, 220 F.3d at 93 (noting that "[a]lthough virtually every company may have the desire to maintain a high bond or credit rating ... not every company has the desire to use its stock to acquire another company”).

140 . Cf. In re 1993 Coming Sec. Litig., No. 93 Civ. 7015, 1996 WL 257603, at *6 (S.D.N.Y. May 15, 1996) (noting that San Leandro "attached no temporal limitation to its holding”).

141 . See Novak, 216 F.3d at 308 (adequate motive generally arises from "the desire to profit from extensive insider sales”); see also Stevelman, 174 F.3d at 85 ("[pjerhaps the most persuasive allegation in the Amended Complaint is the fact that Bingham, along with other Alias officers, sold off large portions of his stockholdings during the period of the misrepresentations”).

142 . See also Complaint ¶ 54 (media quotes defendants Mihir Taneja and Sekharam as reporting that neither sold personal holdings on December 1 or 2).

143 . See, e.g., Kalnit, 264 F.3d at 139 (plaintiffs must assert that individual defendants would receive a "concrete and personal benefit” from the alleged scheme).

144 . See In re Initial Public Offering Sec. Litig. (In re Rediff.com Sec. Litig.), 358 F.Supp.2d 189, 215 (S.D.N.Y.2004) (in the absence of insider stock sales by individual defendants, proposed acquisition by corporate defendant insufficient by itself to establish motive for individual defendants).

145 . See Reply Mem. at 1-3; see also id. at 3 n. 1 (“Given the incompatibility ... between a finding of [scienter] and a recognition that defendants obviously never could have expected the alleged scheme to have succeeded, it therefore should not matter whether such intent is to be inferred from motive and opportunity or recklessness.”).

146 . Examining the allegations separately under the rubrics of "motive and opportunity” and "conscious misbehavior or recklessness” is unduly formalistic and not required by the PSLRA, which merely directs a court to assess whether plaintiff has raised a "strong inference” of scienter. 15 U.S.C. § 78u-4(b)(2). Cf. Novak, 216 F.3d at 311 (discussing how enactment of the PSLRA affected prior Second Circuit precedent concerning pleading of scienter; while prior case law "may be helpful in providing guidance as to how the [PSLRA's] 'strong inference’ standard may be met ... litigants and lower courts need [not] and should not employ or rely on magic words such as 'motive and opportunity' ”).

147 . Defendants cite an antitrust case, Matsushita Elec. Indus. Co. v. Zenith Radio Corp., 475 U.S. 574, 106 S.Ct. 1348, 89 L.Ed.2d 538 (1986), in which the Supreme Court rejected an inference of intent in a predatory pricing case, because the alleged scheme made little economic sense and was unlikely to eventually "pay off." See id. at 592-94, 106 S.Ct. 1348. Cf. id. at 593, 106 S.Ct. 1348 (citation omitted) ("courts should not permit factfinders to infer conspiracies when such inferences are implausible”).

148 . See Kalnit, 264 F.3d at 142 ("[w]here motive is not apparent, it is still possible to plead scienter by identifying circumstances indicating conscious behavior by the defendant, though the strength of the circumstantial allegations must be correspondingly greater.”).

149 . See Complaint ¶ 61; see also id. ¶ 42 (alleging that defendants did not disclose the nature of the FDA approval until December 2). Plaintiffs also make several conclusory allegations regarding defendants’ knowledge or recklessness of the falsity of their statements, see id. ¶¶ 8, 9, 10, 60, 72, 73 which are of course insufficient to establish scienter under the standards of the PSLRA and Rule 9(b). See, e.g., Shields, 25 F.3d at 1129.

In their memorandum of law, plaintiffs also put forward "an additional fact suggesting that Defendants' conduct went a step beyond extreme recklessness”; that the December 1 release was "carefully crafted to be internally ambiguous, describing [Mucotrol] as a 'prescription product’ for the management of oral mucositis/stomatitis.” PI. Opp. at 19. However, plaintiffs offer no support for the proposition that a court can infer a strong inference of scienter from a suspiciously worded statement — which would be a vague standard at best.

150 . Pl. Opp. at 18 (quotation and citation omitted).

151 . See White, 2004 WL 1698628, at *8-10 (plaintiffs failed to plead scienter because, inter alia, defendant’s misleading statements regarding pending litigation were contradicted only by publicly' available court records).

152 . See In re Scholastic Corp. Sec. Litig., 252 F.3d at 76 ("[w]here the complaint alleges that defendants knew facts or had access to non-public information contradicting their public statements, recklessness is adequately pled"); see also Novak, 216 F.3d at 308 ("Where plaintiffs contend defendants [as opposed to the general public] had access to contrary facts, they must specifically identify the reports or statements containing this information”).

153 . Novak, 216 F.3d at 308 (quotation and citation omitted). To the extent that the December 1 Release could have been more clear, plaintiffs have not pled more than that GeoPharma was negligent. Cf. Kdlnit v. Eichler, 99 F.Supp.2d 327, 343 n. 15 (S.D.N.Y.2000) ("where the materiality of [information not disclosed by defendants] is highly debatable at best ... the failure to disclose that release simply cannot lead to a finding of recklessness.”).

154 . To establish transaction causation, plaintiffs invoke the fraud on the market theory to support a presumption of reliance, alleging that GeoPharma shares trade in an efficient market. See Complaint ¶¶ 57, 63-64. Defendants do not dispute the applicability of the presumption.

155 . See Def. Mem. at 23-24.

156 . See id. at 24; see also "GeoPharma Drug for Mouth Inflammation Approved,” Reuters, December 1, 2004, Ex. 3 to 6/6/05 Declaration of Robert A. Scher, counsel to defendant ("Scher Aff.”); "Before the Bell: Humana Up; Sees Hitting Top End of Views”, Dow Jones Newswires, December 1, 2004, Ex. 4 to Scher Aff.

157 . See Def. Mem. at 24 ("to the extent that there was any 'artificial inflation' of the Company's stock price, plaintiffs cannot support an inference that it was the December 1 Press Release, as opposed to the inaccurate news reports, that proximately caused such artificial inflation.”).

158 . See Complaint ¶¶ 47, 49(a).

159

160 . See id. ¶¶ 50, 53.

161

162 . Complaint ¶¶ 78-81. Section 20(a) of the Securities Exchange Act, 15 U.S.C. §§ 78t(a), states, in pertinent part:

Every person who, directly or indirectly, controls any person liable under any provision of this chapter or of any rule or regulation thereunder shall also be liable jointly and severally with and to the same extent as such controlled person to any person to whom such controlled person is liable, unless the controlling person acted in good faith and did not directly induce the act or acts constituting the violation or cause of action.

163 .See Rombach, 355 F.3d at 177-78; see also In re Parmalat Sec. Litig., 383 F.Supp.2d 616, 626 (S.D.N.Y.2005) (same).

164 . See Pl. Opp. at 25 n. 22.

165 . Fed.R.Civ.P. 15(a).

166 . Cortee Indus., Inc. v. Sum Holding L.P., 949 F.2d 42, 48 (2d Cir.1991).